The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Advances in the treatment of chronic lymphocytic leukemia
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about recent advances in the treatment of chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. New drugs, and new treatment strategies are having an impact on the standard of care in the field of CLL, and clinicians are now faced with a variety of treatment options that need to be tailored for each patient.
